CGEN Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 108564 min ago

@ $2.22

Ausgestellt: 14 Feb 2024 @ 15:33

Rendite: -10.81%

Vorheriges Signal: Feb 13 - 21:01

Vorheriges Signal: Kaufen

Rendite: 1.14 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe...

Stats
Tagesvolumen	277 586
Durchschnittsvolumen	532 750
Marktkapitalisierung	177.27M
EPS	$0 ( 2024-03-05 )
Nächstes Ertragsdatum	( $-0.100 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.43
ATR14	$0.00700 (0.35%)

Volumen Korrelation

Lang: 0.30 (neutral)

Kurz: 0.28 (neutral)

Signal:(56.094) Neutral

Compugen Ltd Korrelation

10 Am meisten positiv korreliert
ENTG	0.933
ADSE	0.932
KOPN	0.93
CTIC	0.926
RMBL	0.917
ALR	0.916
MVIS	0.914
MRAM	0.913
ORGO	0.912
NWLI	0.912

10 Am meisten negativ korreliert
ULTA	-0.945
ASO	-0.925
SBNYP	-0.915
TTCF	-0.889
OPTN	-0.888
CDAK	-0.884
CPRX	-0.88
PHCF	-0.87
BNIXU	-0.87
FANH	-0.869

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Compugen Ltd Korrelation - Währung/Rohstoff

-0.17
( neutral )

-0.45
( neutral )

0.00
( neutral )

-0.42
( neutral )

0.31
( neutral )

0.12
( neutral )

Compugen Ltd Finanzdaten

Annual	2023
Umsatz:	$33.46M
Bruttogewinn:	$30.98M (92.59 %)
EPS:	$-0.210

FY	2023
Umsatz:	$33.46M
Bruttogewinn:	$30.98M (92.59 %)
EPS:	$-0.210

FY	2022
Umsatz:	$7.50M
Bruttogewinn:	$6.53M (87.00 %)
EPS:	$-0.390

FY	2021
Umsatz:	$6.00M
Bruttogewinn:	$5.32M (88.67 %)
EPS:	$-0.410

Financial Reports:

No articles found.

Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.